Abstract
During the past two decades many different treatment regimens of combination chemotherapy have been applied in extensive stage small-cell lung cancer (SCLC). This study was carried out to identify whether these modifications have resulted in an improved overall survival for extensive stage during the past two decades. In total, 1111 patients with extensive stage SCLC were included in six consecutive randomised trials in our setting from 1973 until 1992. Of these, 526 patients treated in the early period (1973-1981) were compared with 585 patients treated in the late period (1981-1992) with respect to pretreatment prognostic factors, staging, treatment and outcome. No change in the distribution of prognostic factors was detected and the frequency of patients with extensive stage was equal in the two periods, and no difference in overall response rates and survival was observed (P = 0.49). Median survival in the two periods was 208 days and 215 days, respectively. No stage migration or treatment-related improved outcome was observed in extensive disease. We suggest restricting aggressive treatment to patients with favorable prognosis and long-term survival as a realistic aim.
| Original language | English |
|---|---|
| Journal | Lung Cancer |
| Volume | 20 |
| Issue number | 3 |
| Pages (from-to) | 151-60 |
| Number of pages | 10 |
| ISSN | 0169-5002 |
| Publication status | Published - Jun 1998 |
Keywords
- Adult
- Aged
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Small Cell
- Clinical Trials as Topic
- Female
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Neoplasm Staging
- Outcome and Process Assessment (Health Care)
- Prognosis
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Survival Analysis
- Journal Article
- Research Support, Non-U.S. Gov't
